400 - The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma.
Saved in:
| Title: | 400 - The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma. |
|---|---|
| Authors: | Diallo, B., Massonnet, G., El-Botty, R., Raymondie, C., Howes, C., Wilson, J., Smith, A., Roman-Roman, S., Smith, P., Davies, E., Decaudin, D., Némati, F. |
| Source: | European Journal of Cancer. Dec2016 Supplement 1, Vol. 69, pS132-S132. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09598049 |
|---|---|
| DOI: | 10.1016/S0959-8049(16)32991-4 |
